AstraZeneca (AZN)
92.77
0.00 (0.00%)
Upcoming Events
Latest Headlines
Tezspire hits key endpoints in Phase III eosinophilic esophagitis trial
October 20, 2026 9:02 AM - StreetInsider
TEZSPIRE positive results from Phase III CROSSING trial in eosinophilic esophagitis including symptom improvement, histologic and endoscopic remission presented at United European Gastroenterology Wee
October 20, 2026 9:00 AM - BizWire
Oracle and AstraZeneca sign agreement to improve clinical trials with AI
October 20, 2026 5:58 AM - StreetInsider
AstraZeneca to present data from four Phase III trials at ESMO 2026
October 19, 2026 7:03 AM - StreetInsider
AstraZeneca to present overall survival data from four pivotal Phase III trials in Presidential Symposia at ESMO 2026 featuring Sone-Ve, IMFINZI® (durvalumab), TAGRISSO® (osimertinib) and savolitini
October 19, 2026 7:00 AM - BizWire
AstraZeneca (AZN:LN) (AZN) PT Lowered to GBP139 at HSBC
October 19, 2026 1:31 AM - StreetInsider
AstraZeneca (AZN) spreader of 11694 contracts of October 170, January 180 and January 210 calls as share price up 3.2%
October 15, 2026 2:12 PM - StreetInsider
AstraZeneca partners with insitro on AI-driven cardiometabolic drug discovery
October 15, 2026 6:12 AM - StreetInsider
Myriad Genetics and SOPHiA Genetics team up on prostate cancer test
October 8, 2026 9:01 AM - StreetInsider
SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
October 8, 2026 9:00 AM - PR NewsWire
Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
October 8, 2026 9:00 AM - StreetInsider
Form 4 ASTRAZENECA PLC For: Oct 06 Filed by: Sharma Mani
October 8, 2026 7:12 AM - SEC Filing
AstraZeneca (AZN:LN) (AZN) PT Raised to GBP186 at Citi
October 6, 2026 4:41 AM - StreetInsider
AstraZeneca opens R&D center in Cambridge, Massachusetts
October 5, 2026 12:01 PM - StreetInsider
AstraZeneca opens new global strategic R&D center in Kendall Square, Cambridge, Massachusetts
October 5, 2026 12:01 PM - BizWire
Form 6-K ASTRAZENECA PLC For: Oct 05
October 5, 2026 7:36 AM - SEC Filing
AstraZeneca closes $2 billion equity stake in Summit Therapeutics
October 5, 2026 7:01 AM - StreetInsider
AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics
October 5, 2026 7:00 AM - BizWire
Form 6-K ASTRAZENECA PLC For: Oct 02
October 2, 2026 6:59 AM - SEC Filing
Summit Therapeutics to test ivonescimab with AstraZeneca-Daiichi ADC
October 2, 2026 6:04 AM - StreetInsider
AstraZeneca (AZN) Daiichi Sankyo, AstraZeneca, and Summit to trial Datroway combo
October 2, 2026 2:46 AM - StreetInsider
Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types
October 2, 2026 2:30 AM - BizWire
Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway
October 2, 2026 2:30 AM - BizWire
Form 6-K ASTRAZENECA PLC For: Oct 01
October 1, 2026 11:41 AM - SEC Filing
Form 6-K ASTRAZENECA PLC For: Oct 01
October 1, 2026 11:32 AM - SEC Filing
High-Stakes October has these Biotechs Entering Crucial Stretch
September 29, 2026 12:13 PM - StreetInsider
Form 6-K ASTRAZENECA PLC For: Sep 29
September 29, 2026 6:41 AM - SEC Filing
Summit Therapeutics gets $2B AstraZeneca investment, Citi raises target
September 29, 2026 5:03 AM - StreetInsider
AstraZeneca invests $2B in Summit Therapeutics preferred shares
September 28, 2026 5:33 PM - StreetInsider
AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics
September 28, 2026 5:30 PM - BizWire
FDA grants priority review to AstraZeneca's Imfinzi combo for bladder cancer
September 25, 2026 7:01 AM - StreetInsider
Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin granted Priority Review in the US for patients with muscle-invasive bladder cancer
September 25, 2026 7:00 AM - BizWire
FDA grants priority review to AstraZeneca's Imfinzi combination for bladder cancer
September 25, 2026 6:02 AM - StreetInsider
AstraZeneca to present gefurulimab trial data at neurology meetings
September 24, 2026 5:53 AM - StreetInsider
AstraZeneca extends Young Health Programme with $100m total investment
September 23, 2026 6:06 AM - StreetInsider
AstraZeneca's Trixeo gets EU approval for asthma treatment
September 23, 2026 6:06 AM - StreetInsider
Form 6-K ASTRAZENECA PLC For: Sep 23
September 23, 2026 6:04 AM - SEC Filing
Roche obesity drug shows 15.5% weight loss in diabetes trial
September 22, 2026 7:26 AM - StreetInsider
Form 6-K ASTRAZENECA PLC For: Sep 21
September 21, 2026 7:05 AM - SEC Filing
Form 6-K ASTRAZENECA PLC For: Sep 21
September 21, 2026 6:51 AM - SEC Filing
AstraZeneca's Klygefa receives positive EU approval recommendation
September 18, 2026 9:24 AM - StreetInsider
EU panel backs Enhertu for early HER2-positive breast cancer
September 18, 2026 8:00 AM - StreetInsider
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer
September 18, 2026 8:00 AM - BizWire
Form 6-K ASTRAZENECA PLC For: Sep 18
September 18, 2026 6:34 AM - SEC Filing
FDA grants priority review to AstraZeneca's efzimfotase alfa for bone disease
September 18, 2026 6:09 AM - StreetInsider
AstraZeneca (AZN:LN) (AZN) PT Raised to GBP129 at Kepler Cheuvreux
September 18, 2026 5:04 AM - StreetInsider
Enhertu approved for NHS use in England for breast cancer patients
September 17, 2026 7:37 AM - StreetInsider
Buy the pullback in this large pharma stock: UBS
September 17, 2026 6:00 AM - StreetInsider
Weakness in this biotech stock is a buying opportunity: Stifel
September 16, 2026 1:00 PM - StreetInsider
AstraZeneca (AZN:LN) (AZN) PT Lowered to GBP152 at UBS
September 16, 2026 4:34 AM - StreetInsider
Form 6-K ASTRAZENECA PLC For: Sep 15
September 15, 2026 10:25 AM - SEC Filing
Form 6-K ASTRAZENECA PLC For: Sep 15
September 15, 2026 10:01 AM - SEC Filing
AstraZeneca (AZN:LN) (AZN) PT Lowered to GBP150 at Berenberg
September 15, 2026 4:24 AM - StreetInsider
Deutsche Bank Upgrades AstraZeneca (AZN:LN) (AZN) to Hold
September 15, 2026 3:19 AM - StreetInsider
Form 6-K ASTRAZENECA PLC For: Sep 14
September 14, 2026 7:37 AM - SEC Filing
Enhertu beats standard care in lung cancer trial on key metric
September 14, 2026 4:29 AM - StreetInsider
AstraZeneca's Tagrisso shows 47% death risk reduction at eight years
September 14, 2026 4:29 AM - StreetInsider
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTI
September 13, 2026 9:55 PM - BizWire
TAGRISSO® (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial
September 13, 2026 9:47 PM - BizWire
Enhertu shows 14.3-month PFS in first-line lung cancer trial
September 13, 2026 9:45 PM - StreetInsider
Enhertu® Demonstrated a Median Progression-Free Survival of 14.3 Months as First-Line Therapy in Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial
September 13, 2026 9:45 PM - BizWire
AstraZeneca's camizestrant fails primary endpoint in breast cancer trial
September 11, 2026 4:18 PM - StreetInsider
Form 4 ASTRAZENECA PLC For: Aug 08 Filed by: Sharma Mani
September 11, 2026 4:06 PM - SEC Filing
AstraZeneca (AZN:LN) (AZN) PT Raised to GBP139.20 at HSBC
September 10, 2026 3:28 AM - StreetInsider
RBC Capital Starts AstraZeneca (AZN:LN) (AZN) at Outperform
September 9, 2026 3:37 AM - StreetInsider
Form 6-K ASTRAZENECA PLC For: Sep 08
September 8, 2026 9:05 AM - SEC Filing
Imfinzi plus tarlatamab shows survival gains in lung cancer trial
September 8, 2026 9:01 AM - StreetInsider
IMFINZI® (durvalumab) plus tarlatamab demonstrated a statistically significant and highly clinically meaningful improvement in overall survival and progression-free survival in 1st-line extensive-sta
September 8, 2026 9:00 AM - BizWire
AstraZeneca COPD drug tozorakimab cuts exacerbations in Phase III trials
September 8, 2026 7:50 AM - StreetInsider
Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials
September 8, 2026 7:50 AM - BizWire
Form 6-K ASTRAZENECA PLC For: Sep 08
September 8, 2026 6:29 AM - SEC Filing
AstraZeneca (AZN:LN) (AZN) PT Lowered to GBP160 at Barclays
September 8, 2026 5:38 AM - StreetInsider
FDA grants accelerated approval to AstraZeneca's camizestrant combo
September 7, 2026 5:55 PM - StreetInsider
ETCAMAH® (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer
September 4, 2026 7:03 PM - BizWire
FDA approves AstraZeneca breast cancer drug Etcamah via accelerated path
September 4, 2026 3:41 PM - StreetInsider
BofA Securities Reiterates Buy Rating on AstraZeneca (AZN:LN) (AZN)
September 4, 2026 6:06 AM - StreetInsider
Form 6-K ASTRAZENECA PLC For: Sep 01
September 1, 2026 12:20 PM - SEC Filing
Form 6-K ASTRAZENECA PLC For: Sep 01
September 1, 2026 12:09 PM - SEC Filing
Form 6-K ASTRAZENECA PLC For: Sep 01
September 1, 2026 7:36 AM - SEC Filing
Form 6-K ASTRAZENECA PLC For: Sep 01
September 1, 2026 7:27 AM - SEC Filing
Form 6-K ASTRAZENECA PLC For: Sep 01
September 1, 2026 7:19 AM - SEC Filing
Form 6-K ASTRAZENECA PLC For: Sep 01
September 1, 2026 7:10 AM - SEC Filing
Form 6-K ASTRAZENECA PLC For: Sep 01
September 1, 2026 7:04 AM - SEC Filing
AstraZeneca closes $600M deal for lung cancer drug Zegfrovy
September 1, 2026 7:00 AM - StreetInsider
AstraZeneca completes global license agreement for oral EGFR inhibitor ZEGFROVY® (sunvozertinib) for lung cancer
September 1, 2026 7:00 AM - BizWire
EU approves Enhertu combo for first-line HER2-positive breast cancer
September 1, 2026 6:09 AM - StreetInsider
AstraZeneca acquires worldwide rights to lung cancer drug Zegfrovy
September 1, 2026 6:09 AM - StreetInsider
AstraZeneca's Tagrisso combo shows Phase III benefit in lung cancer
September 1, 2026 6:08 AM - StreetInsider
Enhertu® Plus Pertuzumab Approved in the EU as First New Regimen in More than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer
September 1, 2026 2:30 AM - BizWire
Alnylam stock drops on rival heart trial: Why analysts see core business safe
August 28, 2026 8:25 AM - StreetInsider
Form 6-K ASTRAZENECA PLC For: Aug 27
August 27, 2026 7:05 AM - SEC Filing
TEZSPIRE demonstrates positive Phase III results in eosinophilic esophagitis across both co-primary and all key secondary endpoints
August 27, 2026 7:00 AM - BizWire
AstraZeneca's Tezspire meets endpoints in esophagitis trial
August 27, 2026 6:04 AM - StreetInsider
A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
August 26, 2026 9:20 AM - StreetInsider
Daiichi Sankyo and AstraZeneca start phase 3 urothelial cancer trial
August 26, 2026 7:00 AM - StreetInsider
TROPION-Urothelial04 Phase 3 Trial of Datroway® Initiated as Adjuvant Therapy in Patients with High-Risk Muscle Invasive Urothelial Cancer
August 26, 2026 7:00 AM - BizWire
Form 6-K ASTRAZENECA PLC For: Aug 25
August 25, 2026 7:04 AM - SEC Filing
Form 6-K ASTRAZENECA PLC For: Aug 19
August 19, 2026 9:44 AM - SEC Filing
Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
August 19, 2026 8:56 AM - StreetInsider
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small ce
August 17, 2026 7:30 AM - BizWire
Form 6-K ASTRAZENECA PLC For: Aug 17
August 17, 2026 7:15 AM - SEC Filing
Form 6-K ASTRAZENECA PLC For: Aug 17
August 17, 2026 7:09 AM - SEC Filing
Form 6-K ASTRAZENECA PLC For: Aug 17
August 17, 2026 7:04 AM - SEC Filing
TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer
August 17, 2026 7:00 AM - BizWire
AstraZeneca halts Phase III lung cancer trial after data review
August 17, 2026 6:02 AM - StreetInsider
AstraZeneca's Tagrisso and Orpathys combo meets Phase III goals
August 17, 2026 6:02 AM - StreetInsider
Enhertu meets main goal in phase 3 lung cancer trial
August 17, 2026 2:30 AM - StreetInsider
Enhertu® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival as First-Line Treatment of Patients with HER2 Mutant Advanced Non-Small Cell Lung Ca
August 17, 2026 2:30 AM - BizWire
Morgan Stanley analysts visit National Resilience facility in Ohio, clients include LLY and AZN
August 12, 2026 12:04 PM - StreetInsider
Form 4 ASTRAZENECA PLC For: Aug 06 Filed by: Sharma Mani
August 7, 2026 11:41 AM - SEC Filing
AZN spikes 6% after report it denies AstraZeneca-BMS merger talks
August 5, 2026 8:31 AM - StreetInsider
Exclusive-'No discussions' over AstraZeneca-Bristol Myers deal, senior source says
August 5, 2026 8:14 AM - StreetInsider
'No Discussions' Over Astrazeneca-Bristol Myers Deal, Senior Source Says - Reuters
August 5, 2026 8:07 AM - StreetInsider
SOPHiA Genetics and AstraZeneca team up on two cancer diagnostics
August 4, 2026 6:15 AM - StreetInsider
SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies
August 4, 2026 6:15 AM - PR NewsWire
UBS Reiterates Buy Rating on AstraZeneca (AZN:LN) (AZN)
August 4, 2026 5:33 AM - StreetInsider
Bristol-Myers Squibb and AstraZeneca said to discuss megamerger - can it happen?
August 3, 2026 11:24 AM - StreetInsider
Form 6-K ASTRAZENECA PLC For: Aug 03
August 3, 2026 10:45 AM - SEC Filing
Form 6-K ASTRAZENECA PLC For: Aug 03
August 3, 2026 10:29 AM - SEC Filing
AstraZeneca reviews potential Bristol Myers deal, Barclays comments
August 3, 2026 8:17 AM - StreetInsider
AstraZeneca (AZN) call put ratio 1.7 calls to 1 put into share price lower before the bell
August 3, 2026 5:50 AM - StreetInsider
Bernstein says risk-reward is positively skewed for this pharma stock
August 1, 2026 10:00 PM - StreetInsider
Form 6-K ASTRAZENECA PLC For: Jul 31
July 31, 2026 6:54 AM - SEC Filing
EU approves AstraZeneca and Daiichi Sankyo's Datroway for breast cancer
July 31, 2026 4:06 AM - StreetInsider
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy
July 31, 2026 2:30 AM - BizWire
AstraZeneca (AZN:LN) (AZN) PT Raised to GBP178 at Citi
July 28, 2026 5:06 AM - StreetInsider
AstraZeneca says adjusting drug pricing over Trump policies
July 27, 2026 8:59 AM - StreetInsider
Form 6-K ASTRAZENECA PLC For: Jun 30
July 27, 2026 7:52 AM - SEC Filing
Form 6-K ASTRAZENECA PLC For: Jul 27
July 27, 2026 7:08 AM - SEC Filing
AstraZeneca drug shows survival benefit in gastric cancer trial
July 27, 2026 7:06 AM - StreetInsider
Sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers
July 27, 2026 7:05 AM - BizWire
AstraZeneca results: H1 and Q2 2026
July 27, 2026 7:00 AM - BizWire
Form 6-K ASTRAZENECA PLC For: Jul 27
July 27, 2026 6:57 AM - SEC Filing
AstraZeneca (AZN) Tops Q2 EPS by 14c
July 27, 2026 6:14 AM - StreetInsider
AstraZeneca's Ultomiris misses primary endpoint in adult HSCT-TMA trial
July 27, 2026 6:06 AM - StreetInsider
AstraZeneca drug shows survival benefit in gastric cancer trial
July 27, 2026 6:06 AM - StreetInsider
AstraZeneca (AZN) Q2 earnings preview
July 26, 2026 8:00 PM - StreetInsider
Enhertu combination gets EU approval recommendation for breast cancer
July 24, 2026 7:39 AM - StreetInsider
EU panel backs Enhertu plus pertuzumab for HER2+ breast cancer
July 24, 2026 7:00 AM - StreetInsider
Enhertu® Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer
July 24, 2026 7:00 AM - BizWire
AstraZeneca's Trixeo receives EU recommendation for asthma treatment
July 24, 2026 6:50 AM - StreetInsider
Form 6-K ASTRAZENECA PLC For: Jul 23
July 23, 2026 6:05 AM - SEC Filing
Full Article List
